A BAFFling Association between Malaria Resistance and the Risk of Multiple Sclerosis

B cells are increasingly recognized as a therapeutic target in autoimmune diseases. B-cell–depleting therapy with the use of rituximab, a monoclonal antibody to CD20, is approved for the treatment of rheumatoid arthritis and antineutrophil cytoplasmic antibody–associated vasculitis and is frequently...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 376; no. 17; pp. 1680 - 1681
Main Authors Korn, Thomas, Oukka, Mohamed
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 27.04.2017
Subjects
Animal models
Antigens
Antineutrophil cytoplasmic antibodies
Autoimmune diseases
CD20 antigen
Cell growth
Disease
Humans
Immunotherapy
Ligands
Lupus
Lupus nephritis
Lymphocytes B
Malaria
Monoclonal antibodies
Multiple Sclerosis
Mutation
Nephritis
Rheumatoid arthritis
Risk
Rituximab
Therapeutic applications
Vasculitis
Online AccessGet full text

Cover

More Information
Summary:B cells are increasingly recognized as a therapeutic target in autoimmune diseases. B-cell–depleting therapy with the use of rituximab, a monoclonal antibody to CD20, is approved for the treatment of rheumatoid arthritis and antineutrophil cytoplasmic antibody–associated vasculitis and is frequently used off-label to treat lupus nephritis. 1 The rationale for targeting B cells in multiple sclerosis has remained controversial, particularly because major animal models of the disease do not involve B cells. 2 Nevertheless, rituximab and its almost fully humanized successor, ocrelizumab, were tried in patients with multiple sclerosis and appear to be exceedingly potent in suppressing signs of inflammation in the . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe1700720